Home > News > Biocon and Abraxis announce approval of Abraxane in India
November 29th, 2007
Biocon and Abraxis announce approval of Abraxane in India
Abstract:
Biocon and Abraxis BioScience, an integrated global biopharmaceutical company, have announced the approval by the country's Drug Controller General to market Abraxane for injectable suspension (paclitaxel protein-bound particles) in India for the treatment of breast cancer. Commercial introduction of Abraxane in the Indian market is expected in 2008, following the completion of the appropriate importation certifications. "The approval of Abraxane in India is an important step in providing access to the NAB (nanoparticle albumin bound) technology globally," said Patrick Soon-Shiong, Managing Director, Chairman and Chief Executive Officer of Abraxis. "In partnership with Biocon, we are excited to offer physicians in India this important advance in the treatment of breast cancer."
Source:
expresspharmaonline.com
Related News Press |
Govt.-Legislation/Regulation/Funding/Policy
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Researchers’ approach may protect quantum computers from attacks March 8th, 2024
Optically trapped quantum droplets of light can bind together to form macroscopic complexes March 8th, 2024
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||